XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.1
SEGMENTS
 3 Months Ended
Mar. 31, 2021
SEGMENTS  
11. SEGMENTS

11. SEGMENTS

 

The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.  The Company’s ADMA BioManufacturing segment reflects the Company’s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1).  The Plasma Collection Centers segment as of March 31, 2021 consists of two FDA-licensed source plasma collection facilities, an additional plasma collection facility for which an FDA license is pending, and four other plasma collection facilities under various stages of development. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer.  Summarized financial information concerning reportable segments is shown in the following tables:

 

Three Months Ended March 31, 2021

 

 

ADMA BioManufacturing

 

 

Plasma Collection Centers

 

 

Corporate

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$13,421,043

 

 

$2,591,867

 

 

$35,708

 

 

$16,048,618

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

 

15,449,757

 

 

 

2,320,365

 

 

 

-

 

 

 

17,770,122

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(9,505,689)

 

 

(1,970,841)

 

 

(3,687,719)

 

 

(15,164,249)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest and other expense, net

 

 

(21,513)

 

 

(384)

 

 

(3,193,795)

 

 

(3,215,692)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(9,527,202)

 

 

(1,971,225)

 

 

(6,881,514)

 

 

(18,379,941)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

 

1,012,980

 

 

 

1,558,181

 

 

 

-

 

 

 

2,571,161

 

Depreciation and amortization expense

 

 

1,009,770

 

 

 

217,991

 

 

 

1,867

 

 

 

1,229,628

 

Total assets

 

 

156,535,177

 

 

 

17,397,612

 

 

 

61,734,239

 

 

 

235,667,028

 

Three Months Ended March 31, 2020

 

 

ADMA BioManufacturing

 

 

Plasma Collection Centers

 

 

Corporate

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$7,743,275

 

 

$2,420,761

 

 

$35,708

 

 

$10,199,744

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

 

14,451,954

 

 

 

2,377,272

 

 

 

-

 

 

 

16,829,226

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(12,476,144)

 

 

(457,155)

 

 

(3,836,487)

 

 

(16,769,786)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest and other expense, net

 

 

(238,873)

 

 

-

 

 

 

(2,236,571)

 

 

(2,475,444)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(12,715,017)

 

 

(457,155)

 

 

(6,073,058)

 

 

(19,245,230)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

 

1,914,614

 

 

 

160,262

 

 

 

-

 

 

 

2,074,876

 

Depreciation and amortization expense

 

 

674,973

 

 

 

111,289

 

 

 

2,576

 

 

 

788,838

 

Total assets

 

 

104,645,897

 

 

 

5,376,807

 

 

 

100,501,123

 

 

 

210,523,827